Novel Approaches to Diagnosing and Treating Generalized Pustular Psoriasis - Episode 8

Role of IL-36 in GPP Pathogenesis and Treatment

Published on: March 22, 2025

Aaron Farberg, MD, FAAD , Harrison Nguyen, MD, MBA, MPH, FAAD , Boni Elewski, MD, FAAD , Johann Gudjonsson, MD, PhD, FAAD

Panelists describe the role of the IL-36 pathway in the pathogenesis of generalized pustular psoriasis (GPP) and discuss how IL-36 inhibition can be a key strategy in managing the disease.

Video content above is prompted by the following:

EP. 1: Clinical Presentation and Burden of Disease of Generalized Pustular Psoriasis

EP. 2: Impact of GPP Triggers and Flares on a Patient’s Physical and Mental Health

EP. 3: Approaches to Diagnosing GPP and Distinguishing It From Other Psoriatic Conditions

EP. 4: Challenges for Making a Timely GPP Diagnosis

EP. 5: GPP Pathogenesis and Treatment Goals

EP. 6: Older Treatment Approaches to GPP Management

EP. 7: Addressing the Psychosocial Aspects of GPP Management and the Role of Multidisciplinary Care

Now Viewing

EP. 8: Role of IL-36 in GPP Pathogenesis and Treatment

Describe the role of the IL-36 pathway in the pathogenesis of GPP and how IL-36 inhibition can play a role in disease management.